From Miracle to Retraction: The Barbacid Affair and the Political Economy of Scientific Hope

The so-called Barbacid affair, which emerged in Spain during the spring of 2026, offers a remarkable case study in the contemporary relationship between scientific authority, public expectation, biomedical entrepreneurship, and media communication. At the centre of the controversy lies a study on pancreatic cancer published in the Proceedings of the National Academy of Sciences (PNAS), initially celebrated as a potentially revolutionary breakthrough and later retracted owing to undisclosed conflicts of interest linking several authors to a company established to commercialise the therapies under investigation. The subsequent republication of the study, accompanied by a full disclosure of those interests, transformed what appeared at first to be a question of scientific misconduct into a far more complex reflection on the changing nature of credibility in contemporary science. This essay examines the affair as a symptom of a broader historical transformation: the replacement of the traditional economy of scientific authority by an economy of scientific expectation.

1. The Manufacture of Scientific Hope

Few diseases occupy the contemporary imagination as powerfully as pancreatic cancer. Its exceptionally high mortality rate, the limited effectiveness of existing treatments, and the rapid progression that characterises many cases have transformed it into one of the most feared diagnoses in modern medicine.

It is therefore unsurprising that, when a team led by the Spanish molecular biologist Mariano Barbacid announced that a combination of three targeted agents had completely eliminated pancreatic tumours in experimental mouse models, the news rapidly transcended the boundaries of specialist biomedical literature. Newspapers, television programmes, philanthropic organisations, social media platforms, and public institutions presented the study as evidence that a decisive turning point in pancreatic cancer research might finally have been reached. The language employed by many media outlets frequently approached that traditionally associated with medical miracles rather than experimental oncology.

Yet the original scientific publication had been considerably more cautious. The experiments had been conducted exclusively in animal models. No clinical trial involving human patients had begun. The treatment itself remained experimental, and its translation into clinical practice required years of additional investigation. Indeed, the CNIO itself explicitly acknowledged that the results did not justify immediate human application.

The distance separating scientific prudence from public enthusiasm constitutes the first and perhaps most revealing dimension of the affair.

The sociology of science has long recognised that scientific discoveries do not circulate as neutral facts. They enter complex networks of institutions, media systems, political expectations, philanthropic funding structures, and economic interests. The history of modern medicine repeatedly demonstrates that the public life of a discovery often begins long before its scientific status has been fully established. Hope circulates more rapidly than evidence.

2. Retraction Without Fraud

The dramatic reversal occurred in April 2026, when PNAS withdrew the article.

Barbacid's Research

Specifically, the following is the summary of the study as published by PNAS:

Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest survival rates among all cancers. Recent studies employing RAS inhibitors have paved the way for more effective therapies, although their benefit remains limited, largely because of the rapid emergence of tumour resistance. In the present study, we demonstrate that the genetic ablation of three independent nodes involved in KRAS signalling pathways—one downstream (RAF1), one upstream (EGFR), and one “orthogonal” (STAT3)—results in the complete and permanent regression of orthotopic PDAC tumours driven by KRAS/TP53 mutations. Likewise, a combination of selective inhibitors targeting KRAS (RMC-6236/daraxonrasib), the EGFR family (afatinib), and STAT3 (SD36) induced complete regression of orthotic PDAC tumours, with no evidence of tumour resistance for more than 200 days following treatment. This combination therapy also produced significant regression in both genetically engineered mouse tumours and patient-derived xenografts (PDXs), without tumour recurrence. Importantly, the treatment was well tolerated. Taken together, these findings should guide the development of new clinical studies that may ultimately benefit patients suffering from PDAC.

The reason, however, was neither data fabrication nor experimental error. Editors concluded that relevant conflicts of interest had not been disclosed when the manuscript was submitted. Several authors, including Barbacid himself, possessed financial interests in Vega Oncotargets, a company created to develop therapies against pancreatic cancer and potentially benefit from the research findings.

This distinction is crucial.

The public often interprets retraction as synonymous with scientific falsification. Historically, however, retractions have served multiple functions. Some concern fabricated data. Others involve methodological errors. Still others address ethical and procedural questions. The Barbacid case belongs primarily to this latter category.

The problem was not the experimental observation itself. The problem concerned transparency regarding the economic interests surrounding that observation. Indeed, a revised version of the article was later republished after disclosure of the relevant relationships between the authors and Vega Oncotargets.

What collapsed was therefore not necessarily the scientific result. What collapsed was the presumption of complete independence upon which scientific credibility largely depends.

3. Science, Venture Capital, and the New Economy of Credibility

The affair reveals a deeper structural transformation affecting contemporary biomedical research.

Twentieth-century scientific culture largely operated according to an idealised model in which knowledge production and commercial exploitation remained institutionally distinct. Universities generated knowledge; companies transformed knowledge into products. While the reality was always more complex, the distinction nevertheless retained considerable normative force.

The twenty-first century has witnessed the emergence of a different model. Scientists increasingly become founders, shareholders, patent holders, consultants, and entrepreneurs. Research laboratories function simultaneously as centres of discovery and as nodes within innovation ecosystems oriented toward commercial translation.

This transformation has produced undeniable benefits. Many therapeutic advances would never reach patients without private investment and entrepreneurial activity. Yet the same transformation also generates new vulnerabilities. When the same actors occupy the roles of investigator, patent holder, company founder, public spokesperson, and beneficiary of future commercial success, the traditional mechanisms through which scientific trust is established become more fragile.

The issue is therefore not corruption in its classical sense. It is opacity.

A conflict of interest does not automatically invalidate scientific results. What it does invalidate is the possibility of evaluating those results without complete information.

4. The Spectacle of Anticipation

Perhaps the most revealing aspect of the Barbacid affair lies elsewhere.

The controversy emerged after the study had already been transformed into a public event. Donations had been collected. Media campaigns had been launched. Public expectations had been raised. The image of a potential cure had entered collective consciousness.

In this sense, the affair belongs to a broader history of what might be called the spectacle of anticipation.

Contemporary societies increasingly consume future discoveries before they exist. Scientific results are no longer valued exclusively for what they demonstrate. They are valued for what they promise. The object of circulation is not knowledge itself but expectation.

The Barbacid affair therefore forces us to confront a fundamental question. How can democratic societies preserve confidence in science when scientific communication, commercial interests, philanthropy, media attention, and public hope become inseparably intertwined?

The answer is unlikely to be found in greater scepticism toward science. It lies instead in stronger commitments to transparency, disclosure, and intellectual honesty. Trust is not produced by the absence of interests. It is produced by their visibility.